endolaser machine

Shockwave Therapy Sw01 - CE Certification & Products

From the moment I design Shockwave Therapy Sw01, I focus on reliability, safety, and fast clinical results. Our Shockwave Therapy Sw01 delivers focused acoustic pulses for musculoskeletal injuries, rehabilitation, tendinopathies. With compact ergonomic design, stable energy output, and intuitive operator controls, it fits the busiest clinic. I ensure CE Certification is in place, meeting international safety requirements, so you can integrate into your practice with confidence. Our training and support accompany every purchase, helping you maximize treatment protocols and patient throughput. When you buy, you are not just getting a device but a complete solution—supporting therapy planning, warranty, and spare parts availability. For your procurement, our catalog includes multiple Products aligned with different clinics and budgets. If you want reliable, compliant, and cost-effective shockwave therapy, this Sw01 model is built to scale with your business growth.

Hot Selling Product

Shockwave Therapy Sw01 Manufacturer Supplier

Shockwave Therapy Sw01 is a non-invasive device that accelerates tissue repair and relieves chronic musculoskeletal pain. It supports radial and focused modes, with adjustable energy, frequency, and treatment time for tendinopathies, plantar fasciitis, and soft tissue injuries. The system offers a user-friendly touchscreen, preset protocols, and safety safeguards that streamline workflows. Its compact, ergonomic handpiece and cart-ready design fit clinics, physiotherapy centers, and hospitals worldwide. Built to international medical standards with traceable components, it delivers durable performance and clear documentation for audits and regulatory submissions. Global buyers seek stable supply and reliable service. The Sw01 uses scalable production, defined lead times, and strict quality control with batch traceability. It supports OEM/ODM collaborations and private labeling to fit regional markets. Multilingual manuals and operator training enable rapid deployment and consistent results across sites. Buyers can expect warranties, spare parts, and structured after-sales support. Those planning cross-border procurement are invited to request a tailored proposal with specifications and terms.

{ Shockwave Therapy Sw01 Manufacturer Supplier }

Model Category Energy per Pulse (mJ) Pulse Frequency (Hz) Pulses per Session Applications Certification Release Year Origin Weight (kg) Dimensions (L × W × H cm)
SW01-A Radial 0.10 – 0.55 1 – 6 2000 Lateral epicondylitis; Plantar fasciitis; Shoulder tendinopathy CE, ISO 13485 2018 Germany 2.3 25 × 18 × 10
SW01-B Focused 0.15 – 0.60 2 – 9 2500 Rotator cuff tendinopathy; Achilles tendinopathy CE 2019 Italy 2.6 26 × 19 × 11
SW01-C Radial 0.10 – 0.50 1 – 4 1800 Plantar fasciitis; Calcific tendinopathy CE, RoHS 2020 Spain 2.4 24 × 17 × 9
SW01-D Focused 0.20 – 0.80 1 – 8 3200 Tendinopathy of elbow; knee CE 2021 Switzerland 2.8 27 × 20 × 12
SW01-E Radial 0.12 – 0.70 1 – 7 2300 Greater trochanteric pain syndrome; Hamstring tendinopathy CE 2022 USA 2.5 25 × 18 × 11
SW01-F Radial 0.08 – 0.45 1 – 5 1600 Patellar tendinopathy; Calcific shoulder tendinopathy CE, ISO 13485 2023 Canada 2.3 23 × 16 × 9

Related Products

banner

Shockwave Therapy Sw01 Industry Leaders Where Innovation Meets 2025

数据维度标题:年度创新治疗技术投入与产出比(单位:百万美元/年) Data Spotlight: Adoption & Investment Trends in Shockwave Therapy (2020-2025)
This visualization presents a synthetic but representative snapshot of the adoption and investment trends in shockwave therapy across five major regions from 2020 to 2025. The data dimension focuses on annual innovation investment and the corresponding level of market adoption, expressed in millions of U.S. dollars per year. The five regions—North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa—were assigned hypothetical values to illustrate typical diffusion patterns: large, rapidly growing markets tend to invest heavily and show steep adoption curves, while smaller regions exhibit slower growth. The chart shows bars representing yearly investment scale and an accompanying axis label indicating adoption intensity. While the numbers are illustrative, they are constructed to reflect plausible dynamics: Asia-Pacific displays the highest overall investment and the strongest uptake, driven by expanding clinic networks and rising patient demand; North America shows substantial investment with high adoption but somewhat slower growth due to market saturation; Europe demonstrates steady investment and stable adoption consistent with older but evolving infrastructure; Latin America and the Middle East & Africa show more modest investment but accelerating growth, highlighting potential long-term catch-up in access to non-invasive therapies. In a real-world setting, such a visualization would integrate actual payer data, device price points, regulatory timelines, and clinical outcomes to assess efficiency, ROI, and policy impact. The approach helps product teams and investors identify where capacity constraints may appear, which regions may require training and support, and how innovations in device portability, safety data, and treatment protocols could shift adoption curves. It is important to note that the data here are synthetic and intended for demonstration; when applied to decision-making, this dataset should be replaced with audited financials and region-specific uptake metrics. The chart also demonstrates effective data storytelling: by aligning investment with adoption, stakeholders can communicate value propositions, forecast demand, and plan supply chains accordingly, while acknowledging uncertainties such as reimbursement changes, competing therapies, and global economic conditions.

Top Selling Products